var data={"title":"Rivastigmine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rivastigmine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6920?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rivastigmine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rivastigmine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218918\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Exelon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218919\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Rivastigmine;</li>\n      <li>Exelon;</li>\n      <li>Med-Rivastigmine;</li>\n      <li>Mint-Rivastigmine;</li>\n      <li>Mylan-Rivastigmine;</li>\n      <li>Novo-Rivastigmine;</li>\n      <li>PMS-Rivastigmine;</li>\n      <li>ratio-Rivastigmine;</li>\n      <li>Sandoz-Rivastigmine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218950\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Acetylcholinesterase Inhibitor (Central)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218923\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Exelon oral solution and capsules are bioequivalent.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Exelon oral solution has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alzheimer dementia, mild to moderate:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> Initial: 1.5 mg twice daily; may increase by 3 mg daily (1.5 mg/dose) every 2 weeks based on tolerability (maximum recommended dose: 6 mg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Low body weight:</i> Careful titration and monitoring should be performed in patients with low body weight. In patients &lt;50 kg, monitor closely for toxicities (eg, excessive nausea, vomiting), and consider reducing the dose if such toxicities develop.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> If GI adverse events occur, discontinue treatment for several doses then restart at the same or next lower dosage level; antiemetics have been used to control GI symptoms. If dosing is interrupted for &le;3 days, restart the treatment at the same or lower dose and titrate as previously described.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Transdermal patch: </i>Initial: Apply 4.6 mg/24 hours patch once daily; if well tolerated, may titrate (no sooner than every 4 weeks) to 9.5 mg/24 hours (continue as long as therapeutically beneficial), and then to 13.3 mg/24 hours (maximum dose); doses &gt;13.3 mg/24 hours have not been shown to be more effective and are associated with significant increases in adverse events. Recommended effective dose: Apply 9.5 mg/24 hours or 13.3 mg/24 hours patch once daily; remove old patch and replace with a new patch every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Low body weight:</i> Careful titration and monitoring should be performed in patients with low body weight. In patients &lt;50 kg, monitor closely for toxicities (eg, excessive nausea, vomiting) and consider reducing the maintenance dose to 4.6 mg/24 hour if such toxicities develop.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> If dosing is interrupted for &le;3 days, restart treatment with the same or a lower strength patch. If interrupted for &gt;3 days, reinitiate at 4.6 mg/24 hours and titrate (no sooner than every 4 weeks) to lowest effective maintenance dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conversion from oral therapy: If oral daily dose &lt;6 mg, switch to 4.6 mg/24 hours patch; if oral daily dose 6-12 mg, switch to 9.5 mg/24 hours patch. Apply patch on the day following last oral dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alzheimer dementia, severe: </b> <i>Transdermal patch:</i> Initial: Apply 4.6 mg/24 hours patch once daily. Titrate dose as recommended for transdermal dosing for mild-to-moderate Alzheimer&rsquo;s dementia. Recommended effective dose: Apply 13.3 mg/24 hours patch once daily; remove old patch and replace with a new patch every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Low body weight:</i> Careful titration and monitoring should be performed in patients with low body weight. In patients &lt;50 kg, monitor closely for toxicities (eg, excessive nausea, vomiting) and consider reducing the maintenance dose to 4.6 mg/24 hours if such toxicities develop.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> If dosing is interrupted for &le;3 days, restart treatment with the same or a lower strength patch. If interrupted for &gt;3 days, reinitiate at 4.6 mg/24 hour and titrate (no sooner than every 4 weeks) to lowest effective maintenance dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parkinson-related dementia, mild to moderate:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> Initial: 1.5 mg twice daily; may increase by 3 mg daily (1.5 mg per dose) every 4 weeks based on tolerability (maximum recommended dose: 6 mg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Low body weight:</i> Careful titration and monitoring should be performed in patients with low body weight. In patients &lt;50 kg, monitor closely for toxicities (eg, excessive nausea, vomiting) and consider reducing the dose if such toxicities develop.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> If GI adverse events occur, discontinue treatment for several doses then restart at the same or next lower dosage level; antiemetics have been used to control GI symptoms. If dosing is interrupted for &le;3 days, restart the treatment at the same or lower dose and titrate as previously described.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Transdermal patch:</i> Initial: Apply 4.6 mg/24 hours patch once daily. If well tolerated, may titrate (no sooner than every 4 weeks) to 9.5 mg/24 hours (continue as long as therapeutically beneficial), and then to 13.3 mg/24 hours (maximum dose); doses &gt;13.3 mg/24 hours have not been shown to be more effective and are associated with significant increases in adverse events. Recommended effective dose: Apply 9.5 mg/24 hours or 13.3 mg/24 hours patch once daily; remove old patch and replace with a new patch every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Low body weight:</i> Careful titration and monitoring should be performed in patients with low body weight. In patients &lt;50 kg, monitor closely for toxicities (eg, excessive nausea, vomiting) and consider reducing the maintenance dose to 4.6 mg/24 hour if such toxicities develop.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> If dosing is interrupted for &le;3 days, restart treatment with the same or a lower strength patch. If interrupted for &gt;3 days, reinitiate at 4.6 mg/24 hours and titrate (no sooner than every 4 weeks) to lowest effective maintenance dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lewy body dementia (off-label use):</b> <i>Oral:</i> Initial: 1.5 mg twice daily; may increase by 3 mg daily (1.5 mg per dose) every 2 weeks based on tolerability up to a maximum of 6 mg twice daily (titration lasted up to 8 weeks); study duration was 23 weeks (McKeith 2000). An extension study was conducted in a limited number of patients (at the same dose) for up to 96 weeks (Grace 2001).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218924\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Following oral administration, clearance is reduced in patients &gt;60 years of age; in clinical trials, safety and efficacy were similar between elderly and younger patients. Age was not associated with increased exposure in patients treated transdermally. Titrate dose to individual's tolerance.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218925\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Moderate to severe impairment (CrCl &le;50 mL/minute): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; patients may only be able to tolerate lower doses. Alternatively, an initial dose of 1.5 mg once daily with slow and cautious titration has been recommended (Exelon Canadian product labeling 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal: No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218926\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment (Child-Pugh class A and B): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; clearance is reduced and patients may require lower doses. Alternatively, an initial dose of 1.5 mg once daily with slow and cautious titration has been recommended (Exelon Canadian product labeling 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment (Child-Pugh class A and B): Initial and maximum dose: 4.6 mg/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218897\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Exelon: 1.5 mg [DSC], 3 mg [DSC], 4.5 mg [DSC], 6 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1.5 mg, 3 mg, 4.5 mg, 6 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch 24 Hour, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Exelon: 4.6 mg/24 hr (1 ea, 30 ea); 9.5 mg/24 hr (1 ea, 30 ea); 13.3 mg/24 hr (1 ea, 30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4.6 mg/24 hr (1 ea, 30 ea); 9.5 mg/24 hr (1 ea, 30 ea); 13.3 mg/24 hr (1 ea, 30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Exelon: 2 mg/mL (120 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218882\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28606285\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Exelon oral solution has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218899\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with meals (breakfast and dinner). Capsule should be swallowed whole. Liquid form, which is available for patients who cannot swallow capsules, can be swallowed directly from syringe or mixed with water, soda, or cold fruit juice. Stir well and drink within 4 hours of mixing. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Topical: Apply transdermal patch to upper or lower back (alternatively, may apply to upper arm or chest). Do not use patch if the pouch seal is broken or if the patch is cut, altered, or damaged. Avoid reapplication to same spot of skin for 14 days (eg, may rotate sections of back). Apply to clean, dry, and hairless skin. Patch should be pressed down firmly by applying pressure with the hand over the entire patch for at least 30 seconds, making sure edges stick well. Do not apply to red, irritated, or broken skin. Avoid areas of recent application of lotion or powder. After removal, fold patch to press adhesive surfaces together, place in previously saved pouch, and discard. Avoid eye contact; wash hands after handling patch. Remove old patch and replace with a new patch every  24 hours (at the same time each day). If a dose is missed or if the patch falls off, apply a new patch immediately and replace the following day at the usual application time. Avoid exposing the patch to external sources of heat (eg, sauna, excessive light) for prolonged periods of time. No more than 1 patch should be applied daily and existing patch must be removed prior to applying new patch. Discard any used or unused patches by folding adhesive sides together and dispose of in trash away from children and pets. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218898\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alzheimer dementia: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Treatment of mild to moderate dementia of the Alzheimer type.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal: Treatment of mild, moderate, and severe dementia of the Alzheimer type.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parkinson disease dementia:</b> Treatment of mild to moderate dementia associated with Parkinson disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25472189\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Dementia with Lewy bodies</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46860290\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Exelon may be confused with Exelan (manufacturer)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218889\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (oral: 6% to 21%; transdermal: &le;6%), headache (oral: 4% to 17%; transdermal &le;4%), agitation (transdermal: 1% to 14%), falling (6% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (3% to 26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (oral: 17% to 47%; transdermal: 2% to 10%), vomiting (oral: 13% to 31%; transdermal: 3% to 9%), diarrhea (oral: 5% to 19%; transdermal: &le;7%), anorexia (oral: &le;17%; transdermal: &le;3%), abdominal pain (oral: 13%; transdermal: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site erythema (transdermal: 1% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (oral: 4% to 23%; transdermal: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (1% to 3%), syncope (oral: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (oral: 4% to 9%; transdermal: 2% to 4%), insomnia (1% to 9%), confusion (oral: 8%), depression (2% to 6%), drowsiness (4% to 6%), malaise (oral: 5%), anxiety (1% to 5%), hallucination (2% to 5%), abnormal gait (transdermal: 4%), psychomotor agitation (transdermal: 1% to 3%), aggressive behavior (1% to 3%), exacerbation of Parkinson disease (oral: 1% to 3%), cogwheel rigidity (oral: 1% to 3%), restlessness (oral: 1% to 3%), drug-induced Parkinson disease (oral: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (oral: 2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (oral: 9%), decreased appetite (&le;9%), upper abdominal pain (&le;4%), sialorrhea (oral: 1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (1% to 10%), urinary incontinence (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site pruritus (transdermal: &le;5%), application site irritation (transdermal: &le;3%), application site rash (transdermal: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (2% to 6%;), bradykinesia (3% to 4%), hypokinesia (1% to 4%), dyskinesia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, allergic dermatitis, atrial fibrillation, atrioventricular block, bradycardia, dermatitis (transdermal patch), dystonia, edema, extrapyramidal reaction, gastrointestinal hemorrhage, hepatic failure, hepatitis, hyperacidity, hypersensitivity reaction, nightmares, pancreatitis, seizure, severe vomiting (with esophageal rupture; following inappropriate reinitiation of dose), sick-sinus syndrome, skin blister, Stevens-Johnson syndrome, tachycardia, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218902\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity to rivastigmine, other carbamate derivatives, or any component of the formulation; history of application-site reactions with rivastigmine patch </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling):  Severe hepatic impairment; history of severe skin reactions (eg, allergic dermatitis [disseminated], Stevens-Johnson syndrome) with oral or transdermal rivastigmine   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218886\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergic dermatitis: Disseminated allergic dermatitis has been reported following both oral and transdermal administration. Discontinue use of all routes of rivastigmine therapy in patients who develop disseminated allergic dermatitis.  Use of the transdermal patch may result in allergic contact dermatitis; discontinue therapy if an intense local reaction occurs (eg, increasing erythema, edema, papules, vesicles) and if symptoms do not improve after 48 hours of patch removal. If therapy is still required, oral rivastigmine may be used following negative allergy testing; some patients may not be able to take rivastigmine in any form. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extrapyramidal effects: May exacerbate or induce extrapyramidal symptoms; worsening of symptoms (eg, tremor) in patients with Parkinson disease has been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; GI effects: Significant nausea/vomiting/diarrhea or anorexia/weight loss/decreased appetite are associated with use; occurs more frequently in women and during the titration phase. The incidence and severity of these reactions are dose-related; dehydration may result from prolonged vomiting or diarrhea. Monitor weight during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vagotonic effects: Rivastigmine may have vagotonic effects which may cause bradycardia and/or heart block with or without a history of cardiac disease. Use with caution in patients with sick-sinus syndrome, bradycardia, or other supraventricular conduction abnormalities. Alzheimer treatment guidelines consider bradycardia to be a relative contraindication for use of centrally-active cholinesterase inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peptic ulcer disease: Use with caution in patients at risk of ulcer disease (eg, previous history or NSAID use); may increase gastric acid secretion. Monitor for symptoms active or occult bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory disease: Use with caution in patients with COPD and/or asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Urinary tract obstruction: Use with caution in patients with bladder outlet obstruction or prostatic hyperplasia; cholinomimetics may cause or worsen outflow obstructions, including possible exacerbation of BPH symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Body weight (low/high): Systemic exposure may be increased in patients &lt;50 kg and decreased in patients &gt;100 kg. Consider dose reduction if toxicities develop in patients &lt;50 kg (oral and transdermal). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Smokers: Nicotine increases the clearance of rivastigmine by 23%. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Postmarketing cases of overdose (including rare fatalities) have been reported in association with medication errors/improper use of rivastigmine transdermal patches. No more than 1 patch should be applied daily and existing patch must be removed prior to applying new patch. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Initiation/interruption of therapy: Should be started at lowest dose and titrated; if treatment is interrupted for &gt;3 days, reinstate at the lowest daily dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300010\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218891\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9529&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Rivastigmine may enhance the bradycardic effect of Beta-Blockers. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: Rivastigmine may enhance the adverse/toxic effect of Bromopride. Specifically, the risk of extrapyramidal adverse reactions  may be increased with this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Rivastigmine may enhance the adverse/toxic effect of Metoclopramide. Specifically, the risk of extrapyramidal adverse reactions  may be increased with this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218915\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Food delays absorption by 90 minutes, lowers C<sub>max</sub> by 30% and increases AUC by 30%. Management: Administer with meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218893\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218904\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13907415\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if rivastigmine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218895\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Cognitive function at periodic intervals, symptoms of GI intolerance, weight </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218885\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A deficiency of cortical acetylcholine is thought to account for some of the symptoms of Alzheimer disease and the dementia of Parkinson disease; rivastigmine increases acetylcholine in the central nervous system through reversible inhibition of its hydrolysis by cholinesterase</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218901\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Anticholinesterase activity (CSF): ~10 hours (6 mg oral dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Fasting: Rapid and complete within 1 hour; Transdermal patch: Within 30 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 1.8 to 2.7 L/kg; penetrates blood-brain barrier (CSF levels are ~40% of plasma levels following oral administration) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 40% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively via cholinesterase-mediated hydrolysis in the brain; metabolite undergoes N-demethylation and/or sulfate conjugation hepatically; CYP minimally involved; linear kinetics at 3 mg twice daily, but nonlinear at higher doses </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 36%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Oral: 1.5 hours; Transdermal patch: ~3 hours (after removal) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: 1 hour; Transdermal patch: 8 to 16 hours following first dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (97% as metabolites); feces (0.4%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218903\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Rivastigmine Tartrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (60): $254.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (60): $254.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.5 mg (60): $254.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg (60): $254.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 24-hour</b> (Exelon Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.6 mg/24 hrs (1): $25.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9.5 mg/24 hrs (1): $25.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">13.3 mg/24 hrs (1): $25.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 24-hour</b> (Rivastigmine Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.6 mg/24 hrs (1): $16.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9.5 mg/24 hrs (30): $486.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">13.3 mg/24 hrs (30): $486.09</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218906\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Excelc (KR);</li>\n      <li>Exelon (AE, AR, AT, AU, BB, BE, BG, BH, BO, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HU, ID, IE, IL, IS, IT, JO, JP, KR, KW, LB, LK, LT, LU, MT, MX, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VE, VN, ZA);</li>\n      <li>Exelon Parche (CL);</li>\n      <li>Exelon Parches (AR, CO, EC);</li>\n      <li>Exelon Patch (AE, AT, AU, BR, CY, DK, HK, HR, HU, IL, IN, IS, KR, KW, LB, LT, LU, MY, NL, NZ, PE, PH, PT, QA, RO, SG, SI, SK, TH);</li>\n      <li>Nimvastid (CZ, IE, MT);</li>\n      <li>Prometax (GB, IE, MT);</li>\n      <li>Revelin (TW);</li>\n      <li>RISTIDIC (BG);</li>\n      <li>Rivadem (IN, LK, VN);</li>\n      <li>Rivagmin Patch (KR);</li>\n      <li>Rivamensa Patch (KR);</li>\n      <li>Rivamer (BD, IN);</li>\n      <li>Rivameron Patch (KR);</li>\n      <li>Rivaron Patch (KR);</li>\n      <li>Rivasan (HK);</li>\n      <li>Rivascol (BD);</li>\n      <li>Rivast (TW);</li>\n      <li>Rivasta (TH);</li>\n      <li>Rivastach (JP);</li>\n      <li>Rovacap (BD);</li>\n      <li>Yvastyklyayn (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Emre M, Aarsland D, Albanese A, et al, &ldquo;Rivastigmine for Dementia Associated with Parkinson&rsquo;s Disease,&rdquo; <i>N Engl J Med</i>, 2004, 351(24):2509-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/15590953/pubmed\" target=\"_blank\" id=\"15590953\">15590953</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Exelon (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Exelon (rivastigmine) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Exelon Patch (rivastigmine) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11495394\"></a>Grace J, Daniel S, Stevens T, et al, &ldquo;Long Term Use of Rivastigmine in Patients With Dementia With Lewy Bodies: An Open Label Trial,&rdquo; <i>Int Psychogeriatr</i>, 2001, 13(2):199-205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/11495394/pubmed\" target=\"_blank\" id=\"11495394\">11495394</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hort J, O'Brien JT, Gainotti G, et al, &ldquo;EFNS Guidelines for the Diagnosis and Management of Alzheimer&rsquo;s Disease,&rdquo; <i>Eur J Neurol</i>,  2010, 17(10):1236-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/20831773/pubmed\" target=\"_blank\" id=\"20831773\">20831773</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lefevre G, Sedek G, Jhee SS, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients,&rdquo; <i>Clin Pharmacol Ther</i>, 2008, 83(1):106-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/17522596/pubmed\" target=\"_blank\" id=\"17522596\">17522596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11145488\"></a>McKeith I, Del Ser T, Spano P, et al, &ldquo;Efficacy of Rivastigmine in Dementia With Lewy Bodies: A Randomised, Double-Blind, Placebo-Controlled International Study,&rdquo; <i>Lancet</i>, 2000, 356(9247):2031-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/11145488/pubmed\" target=\"_blank\" id=\"11145488\">11145488</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miyasaki JM, Shannon K, Voon V, et al, &ldquo;Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review). Report of the Quality Standards Subcommittee of the American Academy of Neurology,&rdquo; <i>Neurology</i>, 2006, 66(7):996-1002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/16606910/pubmed\" target=\"_blank\" id=\"16606910\">16606910</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo; <i>Am J Psychiatry</i>, 2007, 164(12 Suppl):5-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/18340692/pubmed\" target=\"_blank\" id=\"18340692\">18340692</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Eijk MM, Roes KC, Honing ML, et al, &quot;Effect of Rivastigmine as an Adjunct to Usual Care With Haloperidol on Duration of Delirium and Mortality in Critically Ill Patients: A Multicentre, Double-Blind, Placebo-Controlled Randomised Trial,&quot; <i>Lancet</i>, 2010, 376(9755):1829-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/21056464/pubmed\" target=\"_blank\" id=\"21056464\">21056464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winblad B, Cummings J, Andreasen N, et al, &ldquo;A Six-Month Double-Blind, Randomized, Placebo-Controlled Study of a Transdermal Patch in Alzheimer's Disease &minus; Rivastigmine Patch Versus Capsule,&rdquo; <i> Int J Geriatr Psychiatry</i>, 2007, 22(5):456-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rivastigmine-drug-information/abstract-text/17380489/pubmed\" target=\"_blank\" id=\"17380489\">17380489</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9529 Version 186.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F218918\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F218919\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F218950\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F218923\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F218924\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F218925\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F218926\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F218897\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F218882\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F28606285\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F218899\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F218898\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25472189\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F46860290\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F218889\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F218902\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F218886\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300010\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F218891\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F218915\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F218893\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F218904\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13907415\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F218895\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F218885\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F218901\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F218903\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F218906\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9529|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rivastigmine-patient-drug-information\" class=\"drug drug_patient\">Rivastigmine: Patient drug information</a></li></ul></div></div>","javascript":null}